LNTH250516P80000
- 2.10
- +0.25+13.51%
Lantheus Newsroom
Unusual Options Activity: C, SCHW and Others Attract Market Bets, C V/OI Ratio Reaches 52.6
Fund Update: KEYBANK NATIONAL ASSOCIATION/OH Added 269,146 Shares of LANTHEUS HOLDINGS ($LNTH) to Their Portfolio
Lantheus Holdings, Inc. (LNTH): Among Stocks With Consistent Growth to Buy Now
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Could Be 49% Below Their Intrinsic Value Estimate
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $110
Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 A.m. Eastern Time
Lantheus Stock Buy Rating Supported by Increased Pylarify Revenue Projections and Updated EPS Estimates
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?
Press Release: Lantheus Completes Acquisition of Evergreen Theragnostics
Lantheus Completes Acquisition Of Evergreen Theragnostics >LNTH
CytoSite Bio Announces Agreement With Lantheus for Granzyme B Targeted PET Imaging Radiotracer for Immunotherapy Assessment
Returns On Capital Are A Standout For Lantheus Holdings (NASDAQ:LNTH)
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Is Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Latest Stock Performance A Reflection Of Its Financial Health?
Lantheus Holdings Analyst Ratings
Lantheus Price Target Lowered to $122 From $127 at B. Riley
B. Riley Cuts Price Target on Lantheus Holdings to $122 From $127, Keeps Buy Rating
Lantheus CFO Marshall Sells 10,000 Common Shares